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Introduction: The development of febrile neutropenia in patients receiving 
myelosuppressive chemotherapies can lead to complications such as infection, 
hospitalization, and interference in continuation of chemotherapy treatments. 
Pegfilgrastim (Neulasta®) is often utilized to decrease the risk of febrile neutropenia; 
however, pegfilgrastim-induced bone pain (PIBP) is a common, and potentially serious, 
side effect. High rates of PIBP suggest that novel prophylactic treatment strategies would 
be of significant clinical benefit, such as with gabapentinoids (e.g. gabapentin, pregabalin). 
The objective of this study is to evaluate the prior use of gabapentinoids in patients with 
lymphoma and to determine if their use demonstrates an effect on incidence of PIBP. 
 
Methods: A retrospective chart review was conducted of patients who were treated for 
diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma and received pegfilgrastim 
(Neulasta®) at the University of North Carolina Medical Center between January 1st and 
December 31st, 2017. Patients were evaluated for incidence of PIBP and use of 
gabapentinoids (gabapentin or pregabalin) during chemotherapy treatment.  
 
Results: A total of 135 patients were identified in the final analysis. The incidence of PIBP 
was 11.1% (N=15) within our DLBCL and follicular population combined, of whom 18.5% 
(N=25) were on a gabapentinoid therapy during the time they received chemotherapy and 
pegfilgrastim treatment (P=0.0456). All patients who received gabapentinoid therapies 
did not report bone pain.  
 
Conclusions: Gabapentinoid use was significantly associated with a decrease in PIBP. 
Patients who reported PIBP did not receive prior gabapentinoids, supporting that 
gabapentinoid prophylaxis could reasonably be implemented. However, further study is 
warranted in a larger population experiencing PIBP to determine if gabapentinoids are 





Febrile neutropenia commonly develops in patients with non-myeloid malignancies 
receiving myelosuppressive chemotherapies. If left untreated, febrile neutropenia can 
lead to serious complications such as infections, hospitalizations, and interference in the 
continuation of chemotherapy treatments, thus affecting treatment outcomes.1 
Pegfilgrastim (Neulasta®) is a PEGylated form of granulocyte colony-stimulating factor 
(G-CSF) often used in patients with non-myeloid malignancies to decrease the duration 
of neutropenia, and thus reduce the risk of febrile neutropenia and overall infection.2 
Pegfilgrastim acts by stimulating granulocyte progenitor cells to increase the proliferation, 
maturation, and activation of neutrophils from the bone marrow.2,3 This long-acting 
formulation may be preferred compared to short-acting G-CSFs (such as filgrastim) due 
to less frequent administration and patient convenience.1  
 
Despite its numerous benefits, a common side effect of all G-CSF agents is skeletal 
and bone pain; this side effect is collectively termed pegfilgrastim-induced bone pain 
(PIBP) when patients receive pegfilgrastim. Experiencing PIBP can interfere with patient 
medication adherence or willingness to continue chemotherapy, therefore impacting the 
anti-tumor efficacy of medication therapy.4,5 Reports of the incidence rates of PIBP within 
clinical trials have been variable, ranging from as low as 6.4% to as high as 71.3%.5,6 
Based on current literature on the incidence rates of PIBP (Appendix A), a majority the 
population previously studied is on average Caucasian females diagnosed with breast 
cancer. The varying incidence of PIBP observed in literature could be due to potential 
factors that have not yet been studied, such as: type of cancer diagnosis, use of 
gabapentinoids (i.e. gabapentin, pregabalin) for prior pain management, pre-existing 
comorbidities, and differences in initial patient health performance. All of these factors 
could be contributing to the variations observed in incidence rates of PIBP. These reports 
of high rates of PIBP along with the drastic effects on a patient’s quality of life suggest 
that prophylactic treatment strategies would be of significant clinical benefit.4 
 
Traditionally, NSAIDs and opioids have been used to treat PIBP once it occurs; but 
limitations exist in using these methods, such as severe pain that is refractory to NSAIDs 
or the undesirable side effects and social stigmas of opioids.5 Pregabalin (Lyrica®) and 
gabapentin (Neurontin®) are GABA analogues that are often prescribed to treat various 
types of neuropathic (i.e. nerve-related) pain such as postherpetic neuralgia, diabetic 
neuropathy, and fibromyalgia, but are not currently indicated to treat bone pain.7,8 The 
analgesic properties of pregabalin and gabapentin have been suggested to be of aid in 
cancer patients experiencing PIBP due to the role of GABA signaling on nerve endings 
to modulate pain signals.9,10,11 Therefore, the use of GABA-based therapies in patients 
experiencing PIBP may serve as a more tolerable alternative method to NSAIDS or 
opioids in order to treat bone pain in patients receiving pegfilgrastim. However, due to the 
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various indications for these gabapentinoid therapies, patients may in fact already be 
receiving gabapentinoids at the time of pegfilgrastim administration, and it is possible 
some patients may have received a prophylactic benefit due to this pre-existing therapy. 
This is supported by a previous phase II clinical trial which sought to evaluate pregabalin 
prophylaxis of PIBP (NCT03407430) but closed due to accrual due in part to patients 
already being on some form of gabapentinoids (primarily gabapentin).12  
 
Based on this historical information, it is possible that patients may have had 
‘opportunistic’ prophylaxis with gabapentinoids being administered for other indications, 
thus affecting the incidence of PIBP. In addition, the literature (Appendix A) is also 
primarily skewed towards a female breast cancer population, where a significant number 
of patients receiving pegfilgrastim may have hematologic malignancies (such as 
lymphoma). Therefore, this study sought to assess three primary objectives: 1) to 
evaluate the incidence of bone pain in patients with lymphoma; 2) to estimate the use of 
pregabalin and gabapentin in patients with lymphoma; and 3) to evaluate the difference, 





Study Participants. This research was approved by the University of North Carolina 
(UNC) Biomedical Institutional Review Board (UNC IRB 17-3361). Eligible patients were 
adults aged 18 or older, received treatment for diffuse large B-cell lymphoma (DLBCL) or 
follicular lymphoma at the UNC Medical Center Cancer Hospital between January 01, 
2017 to December 31, 2017, and received pegfilgrastim therapy during time of their 
chemotherapy treatment. Patients were excluded if they did not receive chemotherapy 
treatment for DLBCL or follicular lymphoma, or if pegfilgrastim was not administered as 
part of their chemotherapy treatment.  
 
Study Endpoints. The primary endpoint was to compare the incidence of PIBP-
related events to gabapentinoid therapy (gabapentin or pregabalin) usage in patients with 
DLBCL or follicular lymphoma who received pegfilgrastim therapy. Secondary endpoints 
included separately evaluating the incidence of PIBP in patients with DLBCL or follicular 
lymphoma, and the use of gabapentinoids in the studied lymphoma population.  
 
Study Design. A retrospective chart review was conducted for eligible patients who 
received cytotoxic chemotherapy for DLBCL or follicular lymphoma that required the 
administration of pegfilgrastim as part of scheduled therapy at the UNC Medical Center 
Cancer Hospital. Patients who received treatment for DLBCL or follicular lymphoma (FL) 
and pegfilgrastim in 2017 were identified by IT specialists through the Carolina Data 
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Warehouse for Health (CDWH) and Department of Pharmacy Analytics Group. The 
following information were included in the initial electronic data mining process: basic 
patient demographics (age at time of treatment, gender, and race), chemotherapy 
treatment regimen, time of pegfilgrastim administration, and pregabalin and/or 
gabapentin use (gabapentinoids).  
 
These patients then underwent manual electronic record review and reconciliation to 
collect data including: timing of pegfilgrastim administration relative to chemotherapy 
treatment, timing of gabapentinoid use relative to chemotherapy treatment, remaining 
baseline characteristics (weight, height, BSA, ECOG score), and presence of 
pegfilgrastim-induced bone pain. Factors that are hypothesized to influence the rates of 
PIBP or gabapentinoids such as age, gender, race, or ECOG score were analyzed as 
secondary endpoints. Each patient’s creatinine clearance was calculated using the 
Cockcroft-Gault Equation. Patients charts where ECOG scores were not reported were 
marked as missing data. ECOG scores that were not whole numbers were rounded up to 
the next nearest whole number (e.g. 1.5 was rounded to 2) because such numbers 
indicate that patient is at a more severe condition than the lower end of the estimated 
score.  
 
Gabapentinoid therapy usage was defined as the use of pregabalin or gabapentin 
during time of receiving chemotherapy. Patients where gabapentinoid use ended prior to 
starting chemotherapy, or where gabapentinoids were initiated after the conclusion of 
chemotherapy treatment were classified as “non-users” of gabapentinoids. Presence of 
bone pain was classified categorically, and it was identified by searching “bone pain” and 
“pain” in the patient profiles. Patients were identified as having PIBP if notes stated as 
such by healthcare professionals, or if the notes indicated that bone pain development 
was likely due to pegfilgrastim use. Data for the incidence of PIBP and use of 
gabapentinoids were initially collected and evaluated as separate data points, and they 
were then combined to formulate the primary endpoint of comparing PIBP-related events 
to gabapentinoid usage in patients with lymphoma who received pegfilgrastim therapy. 
 
Statistical Analysis. Continuous variables were summarized as means with standard 
deviation or median and range, as appropriate. Categorical variables were summarized 
by absolute frequencies and percentages.  
 
Based on a previous study by Kirshner et al. reporting incidence of bone pain after 
pegfilgrastim therapy, a similar incidence of 71% was predicted of enrolled patients in this 
study.5 A one-group Chi2 test with a 0.050 two-sided significance level will have 80% 
power to detect a 5% difference between the null hypothesis proportion of 0.710 and the 
alternative proportion of 0.760 when the sample size is 624. However, even a one-group 
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Chi2 test with a 0.050 two-sided significance level will have 80% power to detect the 
difference between the null hypothesis proportion of 0.710 and the alternative proportion 
of 0.780 when the sample size is 313. In the secondary analysis comparing factors 
contributing to gabapentinoid use, Fisher’s exact test and Wilcoxon two-sample test were 
used to compare differences between the covariates observed between two groups.  
 
RESULTS 
Patient Selection & Characteristics. CDWH identified 234 entries within the 
electronic health record system that met inclusion criteria. Of the 234 entries, 85 entries 
were excluded due to lack of pegfilgrastim use during the duration of chemotherapy 
treatment, or they were excluded due to lack of DLBCL or follicular lymphoma treatment 
during pegfilgrastim use. Some patients received multiple types of chemotherapy 
regiments for their respective DLBCL or follicular lymphoma. Therefore, the final 149 
entries were represented by a total 135 patients, whose data were used in the final data 
analysis. 
 
Of the 135 patients included in this analysis, the average mean age was 65.5 years 
old, 51% were female, and 75% were White or Caucasian (Table 1). Of the DLBCL or 
follicular lymphoma chemotherapy treatments received necessitating pegfilgrastim 
therapy, the majority of patients received R-CHOP (39%) or R-DA-EPOCH (13%). Of 
those who were receiving chemotherapy, the majority of patients were of good 
performance status (74% at ECOG 0 or 1 and 27% ECOG ³ 2).  
 
TABLE 1. Baseline characteristics of patients (n = 135) who received chemotherapy 
pegfilgrastim for DLBCL or follicular lymphoma in 2017 at the North Carolina Cancer Hospital. 
Demographics Race 
Age (years) 65.5 + 13.5 White/Caucasian 101 (74.8%) 
Height (cm) 169.6 + 16.4 Black/African American 17 (12.6%) 
BSA (m2) 1.97 + 0.3 Asian 4 (3.0%) 
CrCl (mL/min) 97.6 + 50.9 American Indian/Alaskan Native 1 (0.7%) 
Female 66 (49%) Other Pacific Islander 2 (0.7%) 
Chemotherapy Treatment Other Race 11 (8.1%) 
R-CHOP 53 (39.3%) ECOG Status 
R-DA-EPOCH 18 (13.3%) 0 43 (37.7%) 
Bendamustine/Rituximab 16 (11.9%) 1 41 (36.0%) 
R-Mini-CHOP 7 (5.2%) ≥ 2 30 (26.5%) 
R-DHAP 2 (1.5%)  
RICE 2 (1.5%) 
CHOP 2 (1.5%) 
R-CEOP 4 (3.0%) 
R-CHOP: rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone 
R-DA-EPOCH: rituximab with dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin 
R-Mini-CHOP: Rituximab and reduced dose CHOP  
R-DHAP: rituximab, dexamethasone, cytarabine, cisplatin  
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RICE: rituximab, ifosfamide, carboplatin, etoposide  
CHOP: cyclophosphamide, doxorubicin, vincristine, and prednisone 
R-CEOP: rituximab, etoposide, vincristine, and prednisone 
ECOG: Eastern Cooperative Oncology Group 
 
 PIBP Incidence & GABA Therapy Use. The first aim of the study was to evaluate 
the incidence of PIBP in the studied population. Of the 135 patients in the final analysis, 
15 patients (11%) had reports of PIBP, with N=13 and N=2 from the DLBCL and follicular 
groups, respectively. Of those who experienced PIBP, loratadine, acetaminophen, and 
opioids were commonly used to treat pain. One patient who experienced PIBP stated that 
oxycodone did not help with pain, while another patient reported that pain improved after 
switching from pegfilgrastim to filgrastim. In the second primary objective evaluating the 
use of gabapentinoids during chemotherapy treatment, 25 patients (19%) received 
gabapentinoids during the course of their chemotherapy (Table 2). Of those who received 
gabapentinoids, gabapentin (N=23) was more commonly used than pregabalin (N=2 
patients). Of the indications for GABA therapy use, the most common indications were 
preexisting neuropathic pain (40%), diabetic neuropathy (20%), and chronic pain (16%) 
(Table 2). Among patients who utilized gabapentinoid therapies (N=25), 600 mg per day 
was the most common total daily dosing regimen (N=7), followed by 900 mg per day 
(N=5), and greater than or equal to 1200 mg per day (N=6). 
 
TABLE 2. Use of GABA therapies patients who received lymphoma treatment and 
pegfilgrastim in 2017 at UNC Health Care Cancer Hospital. 
Yes 23 (19%) 
Gabapentin 23 (17%) 
Most Common Indications for Gabapentinoid Use: 
Neuropathic Pain (40.0%), 
Diabetic Neuropathy (20.0%),  
Chronic pain (16.0%),  
Others: 
Sleep Aid, Restless Leg Syndrome, Postherpetic 
Neuralgia (4% each) 
Pregabalin 2 (1.5%) 
No 97 (81%) 
 
 In the third objective evaluating the association gabapentinoid therapy use to the 
incidence of PIBP, 21% of patients who did not report bone pain had exposure to 
gabapentinoids, and no gabapentinoid use was documented in patients who reported 
bone pain (Figure 1). The use of gabapentinoids in the DLBCL and follicular lymphoma 
groups combined was associated with a decreased incidence of PIBP while receiving 
pegfilgrastim therapy (P=0.0456). However, this significant decrease in PIBP was not 
observed in the sub-analysis of the DLBCL or the follicular group alone (P=0.0662 and 




FIGURE 1. The incidence of PIBP in patients who received gabapentinoids. Gabapentinoid use refers 
to the use of either gabapentin or pregabalin during time of receiving chemotherapy treatment for DLBCL 
and receiving pegfilgrastim therapy. The combined DLBCL and follicular lymphoma population showed a 
significant association (P=0.0456) in gabapentinoid use and a decrease in incidence of PIBP. However, the 
DLBCL group and follicular groups alone did not show a significant association (P=0.0662, N=108 and 
P=1.000, N=27, respectively). Based on current results, the role of gabapentinoids in reducing the incidence 
of PIBP is limited.  
 
DISCUSSION  
Although many proposed mechanisms of PIBP exist, one of the common theories is 
that the G-CSF receptors found on nerve fibers modulate pain signals in cancer-related 
bone pain.13 Overstimulation of these receptors on the nerve endings by pegfilgrastim is 
proposed to induce PIBP and the various other nerve-related pain associated with G-CSF 
use.13 NSAIDs have traditionally been used to treat PIBP due to its evidence of analgesic 
effects in patients receiving pegfilgrastim.5 However, NSAID therapy alone is insufficient 
in treating bone pain due to a low response in only ~10% of patients, and side effects 
such as gastrointestinal bleeding are of concern in this elderly population.5 Opioids have 
also been commonly used in pain management and serve as a secondary option for 
patients who cannot tolerate NSAIDs or have intractable pain on NSAID therapy. 
However, they have a high risk of addiction, withdrawal symptoms, fatal respiratory 
depression, and sedation, and therefore their use is suggested to be minimized. 
Gabapentinoid therapies have been theorized to help prevent PIBP by targeting the bone 
marrow nerve fibers and acting as GABA analogues to inhibit signal transduction to 
reduce pain.9,10,11 Antihistamines have been studied (loratadine being the most common) 
for its effects on PIBP due to histamine modulating effects of G-CSFs in causing 
inflammation and pain, but data is controversial in their effectiveness.14,15 Despite the 
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common use of loratadine in clinical practice in these patients, the NOLAN study by 
Kirshner and colleagues comparing naproxen, loratadine, and placebo for the treatment 
of PIBP showed no statistically significant results among the three treatment groups.16 
Although in clinical practice, patients may still have been given these medications due to 
their ease of administration and tolerability as loratadine resulted in fewer side effects and 
discontinuation of drug compared to naproxen in the NOLAN study. With the lack of a 
statistically proven prophylactic agent, gabapentinoid therapies are being explored  as a 
potential safe prophylactic treatment of PIBP in addition to traditional bone pain 
management options.  
 
The DLBCL study population in this study had an approximately 1:1 female to male 
ratio, which is more diverse than what has been observed so far in literature, where 
analysis is predominantly consisting of a female patient population diagnosed with breast 
cancer (Appendix A). Most of the ethnicities observed were Caucasian (73%), which is 
representative of the population that exists in literature (Appendix A). The most common 
type of chemotherapy treatment received was R-CHOP, which is also consistent as a 
standard chemotherapy regimen in patients diagnosed with DLBCL.17 The majority of 
patients had an ECOG Score of 0 or 1 , with fewer patients who had ECOG scores ³ 2 
(indicating a poorer health status).18 This ECOG Score distribution indicates that the 
patient population were in a relatively healthy condition when initiating chemotherapy 
regimen and pegfilgrastim therapy.  
 
Although the rate of experienced PIBP in this study is lower than the original predicted 
rates of 71% based on a study by Kirshner et al., this difference could be due to the 
relatively healthy population of DLBCL and follicular lymphoma patients enrolled in the 
study, as indicated by the ECOG Score distribution.5 Patients receiving gabapentinoids 
were hypothesized to have higher ECOG Scores compared to those who did not receive 
gabapentinoids, but no association was found, further supporting that patients in this 
study were of better functional and health status. A statically significant association 
between gabapentinoid use and the incidence of PIBP supports the hypothesis that 
gabapentinoids may provide prophylactic benefits in preventing PIBP. Although this 
association was not observed in the sub-analysis of the DLBCL and follicular groups 
alone, this could be attributed to the low number of patients who received gabapentinoids 
during chemotherapy as well as the lower than expected number of patients who did not 
report PIBP.  
 
Of patients who received gabapentinoids, most were not on therapeutic doses for pain 
treatment, which is defined as gabapentin 1,200 mg per day or greater, and pregabalin 
300 mg or greater.19 Only 7 patients were receiving therapeutic doses of gabapentin or 
pregabalin, but other patients may not have been on therapeutic doses due to the titration 
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period required for side effect monitoring. Side effects were not reported for patients 
based on chart reviews, but common side effects that patients can experience include 
drowsiness and dizziness. Gabapentinoids must also be adjusted for renal function and 
tapered upon discontinuation. The average estimated creatinine clearance of this study 
population was ³ 60 mL/min, indicating that average patient in this study had adequate 
renal function for normal dosing of gabapentinoids. For patients whose creatinine 
clearance falls under 60 mL/min, renal function can be monitored in the outpatient setting 
to ensure safe dosing regimens in addition to titrating based on side effects and efficacy.  
 
Limitations of this study included a small sample size in the PIBP group and 
gabapentinoid usage group. Having a larger sample size can aid in a better reflection of 
the general population as well as adding to the validity of the study. A specific subset of 
the lymphoma population (i.e. DLBCL and follicular) was studied, but further research 
should be completed in the breast cancer and leukemia population in order to provide a 
more robust data set for analysis through accruing more patients with gabapentinoid use 
and/or reports of PIBP. Another limitation in this study is the lack of comprehensive patient 
medication lists. A comprehensive medication list for all patients, regardless of PIBP 
status or gabapentinoid use, can provide data of all potential medications helping with 
pain management or providing prophylactic benefits for pain prevention that was not 
considered in this study.  
 
In summary, gabapentinoid use was significantly associated with a decrease in the 
incidence of PIBP in patients receiving chemotherapy treatment for DLBCL or follicular 
lymphoma while receiving pegfilgrastim administration. However, this data is difficult to 
interpret due to the lack of significance observed in the subanalysis of the DLBCL or 
follicular groups alone. Although an overall association was found between gabapentinoid 
use and PIBP incidence, further analysis is warranted to further explore the role of 
gabapentinoids in preventing PIBP.  
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Supplemental Materials  
Appendix A. Summary of literature evaluating incidence of pegfilgrastim-induced bone pain.  
Investigators Study Design 
Total 
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Pegfilgrastim   
VS.  
Balugrastim 




Hecht et al.28 Randomized 
Placebo-
controlled 







10.5% 62.4 NR 34% 
♀ 
Colorectal 









6.4% 51 100% Asian 100% 
♀ 
Breast 
+ The population represents the pegfilgrastim-only patient population used in the analysis of pegfilgrastim-induced bone pain.  
** Severe pain is defined as pain scores > 5 on a scale of 1 to 10.  
NR: Not reported; NSCLC: non-small cell lung cancer; NHL: non-Hodgkin’s lymphoma; HL: Hodgkin’s lymphoma.  
 
 
 
